Novel Targets in Reducing Cardiac Fibrosis as a Preventive Tool for Cardiovascular Diseases. Why Always Treat Them? A Review Article by Gizaw, Kaleab
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online) DOI: 10.7176/JNSR 
Vol.9, No.17, 2019 
 
14 
Novel Targets in Reducing Cardiac Fibrosis as a Preventive Tool 
for Cardiovascular Diseases. Why Always Treat Them? A Review 
Article 
 
Kaleab Gizaw 
Institute of Health Sciences Jimma University 
 
Abstract 
Cardiovascular diseases are the primary causes of death worldwide.  These days its mortality and deadliness is 
rising dramatically. Cardiac fibrosis, one of the leading causes of heart diseases, is a common pathological process 
in cardiac disease. It can also cause sudden death even in those without cardiac symptoms. Experimental studies 
in animals have identified important pathways such as the Renin-Angiotensin-Aldosterone System (RAAS) and 
the endothelin pathway that contribute to fibrosis formation. Currently different groups of drugs are used for 
treatment of cardiac fibrosis including antihypertensive, anti-inflammatory and cardioprotective agents. Despite 
the availability of these agents, the prevalence of heart failure and resistant hypertension is increasing. Therefore 
the search for novel targets is not a questionable issue. Recently different studies are being conducted for treatment 
of cardiac fibrosis specifically acting on epigenetics (ex. MicroRNAs), Receptors (ex. Adenosine receptors), 
Enzymes (ex. Lysl Oxidase like 2) and Oxidative stress (ex. N-Acetylcysteine). Therefore the current review looks 
for promising novel targets aiming at reversing cardiac fibrosis as a preventive tool for cardiovascular diseases. 
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Abbreviations  
ANG  Angiotensin 
CF   Cardiac Fibrosis  
CHF   Congestive Heart Failure  
ECM   Extra Cellular Matrix  
ET-1   Endothelin type 1  
IL  Interleukin 
LOXL2   Lysyl Oxidase-Like 2  
MI   Myocardial Infarction  
MiRNA  Micro Ribo Nucleic Acid  
NAC   N-Acetylcysteine 
RAAS  Renin Angiotensin Aldosterone System  
ROS   Reactive Oxygen Species 
TGF-β   Transforming Growth Factor Beta 
TNF-α  Tissue Necrosis Factor alpha 
 
1. Background  
1.1 Introduction  
Cardiovascular diseases (CVDs) are the primary causes of death worldwide, with 17.5 million deaths from CVD 
in 2012 representing 31% of all global deaths that year (Duygu et al., 2013). Fibrosis appears as a common 
pathophysiological phenomenon, especially during the development and progression of cardiovascular diseases. 
The normal cardiac anatomy is progressively modified by the excessive deposition of extracellular matrix with 
reduction of microvasculature and disruption of normal myocardial structures (Porter and Turner, 2009, Roubille 
et al., 2014, and M.Gyongyosi et al., 2017).    
Myocardial / Cardiac fibrosis refers to a variety of quantitative and qualitative changes in the interstitial 
myocardial collagen network that occur in response to cardiac ischemic insults, systemic diseases, drugs, or any 
other harmful stimulus affecting the circulatory system or the heart itself (M.Gyongyosi et al.,2017).  
It is a result of a variety of injurious insults of different causes to cardiac tissue, which ultimately culminates 
in destruction of physiological tissue architecture and progressive organ dysfunction. Histologically, it is 
characterized by activation/proliferation of fibroblasts and excessive matrix deposition, including collagen 
(Roubille et al., 2014 and M.Gyongyosi et al., 2017). 
Cardiac fibrosis leads to irreversible death of myocardial cells and is associated with increased stiffness that 
contributes significantly to diastolic dysfunction (Porter and Turner, 2009, Biernacka et al.,2011 and Roubille et 
al., 2014), whereas regression of fibrosis is believed to improve cardiac function (Jalil et al.,1989 and Roubille et 
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al., 2014). 
Myocardial fibrosis is a significant global health problem associated with nearly all forms of heart diseases 
including heart failure (Biernacka et al., 2011, Roubille et al., 2014, Travers et al., 2016 and Adebiyi et al.,2016), 
myocardial infarction (Jalil et al.,1989) and cardiac arrhythmias (Hrayr et al.,2011, Travers et al., 2016 and 
M.Gyongyosi et al.,2017) among others.   
Myocardial fibrosis (MF) is a distinct structural feature of cardiac remodeling and a common finding in the 
histopathological examinations of the myocardium and a predisposing risk factor for the development of heart 
failure in patients in type 1 diabetes mellitus as well (Adebiyi et al.,2016 and Norshige et al.,2011). 
Increased fibrosis has been observed around trabeculae and in the interstitial spaces of the atrial myocardium 
during Congestive heart failure (CHF) in both animal models and human biopsies. Moreover, there are profound 
changes in the atrial electrical properties including depressed excitability, increased refractoriness, and conduction 
slowing or block, which have been related to the degree of interstitial fibrosis. This atrial remodeling is likely 
responsible for the composition of the substrate for atrial fibrillation (AF), the incidence of which is increased 
during CHF (M.Gyongyosi et al., 2017 and Hrayr et al., 2011). 
 
1.2 Classification of cardiac fibrosis  
Cardiac fibrosis can be categorized into two types: reactive fibrosis and replacement fibrosis (also called reparative 
fibrosis). The term “reactive interstitial fibrosis” is used to describe expansion of the cardiac interstitial space in 
the absence of significant cardiomyocyte loss; in contrast “reparative fibrosis” refers to the formation of a scar in 
response to myocardial infarction. Replacement fibrosis often occurs after Myocardial Infarction (MI) when large 
numbers of cardiac myocytes undergo necrosis. Myocyte necrosis triggers a series of events including immune 
cell infiltration, inflammation, new vessel formation, removal of necrotic tissue, and eventually the replacement 
of damaged tissue with collagen dominated fibrotic tissue that prevents cardiac muscle from rupture. In addition 
to scar formation at the infarcted area, the remote noninfarcted regions can develop fibrosis in the interstitial spaces, 
which is referred to as reactive fibrosis or interstitial fibrosis. Interstitial fibrosis can also occur in disease 
conditions that often involve the activation of Renin-Angiotensin-Aldosterone System (RAAS), TGF-β, TNF-α or 
other profibrotic signaling pathways (Weber et al., 1992 and Prabu and Frangogiannis, 2016). 
It can either be localized which is mostly evidenced by scarring following myocardial infarction [MI]), or 
diffuse which is commonly seen in dilated cardiomyopathy) (Jalil et al., 1989 and Biernacka et al., 2011).   
 
1.3 Pathogenesis  
Tissue fibrosis is characterized by an accumulation of proteins, especially collagen, in the extracellular space, 
which are secreted by profibrotic cells such as fibroblasts. As a result of the excessive accumulation of proteins, 
nearby cells become hypotrophic and less numerous and their normal activity is hampered (Roubille et al., 2014 
and Anderson et al., 1979). 
Cardiomyocytes, fibroblasts, and vascular cells in the heart are connected by a complex matrix principally 
composed of fibrillar collagen, which is instrumental in preserving structural integrity and plasticity. In the 
diseased heart, the matrix undergoes structural and sub cellular changes that progressively influence heart function. 
Beyond the cardiomyocyte-centric view of heart injury, it is now accepted that alterations of the cardiac 
extracellular matrix (ECM) and cardiac remodeling play a major role in the development and evolution of cardiac 
diseases leading to heart failure (HF) and other cardiovascular diseases (Travers et al.,2016 and Biernacka et 
al.,2011). 
Myocardial fibrosis is responsible for alteration of level of soluble collagen. There are three different types 
of collagen that shows accumulation due the generation of myocardial fibrosis. Type I collagen showed a high 
level as compared to the others. Type I collagen is responsible for stiffening of ventricles which further alters 
myocardial autorhythmic activity and contraction (Thomas et al., 2007). 
Cardiac fibroblasts are derived from epithelial and endothelial cells during embryonic development of the 
heart in a process called epithelial mesenchymal transition (EMT) and endothelial–mesenchymal transition 
(EndMT) respectively (Turner et al., 2009, Prabu and Frangogiannis, 2016 and Thomas et al., 2007).  
Resident cardiac fibroblasts are considered the major source but other cell types such as vascular endothelial 
cells, perivascular cells, and progenitor cells have been shown to differentiate into myofibroblasts (Travers et al., 
2016 and Thomas et al., 2007). 
Fibrosis develops when the body's natural wound-healing process goes awry. Under normal (adaptive) 
conditions of wound healing, specialized cells known as fibroblasts become activated by transforming to 
myofibroblast. The myofibroblasts then undergo proliferation causing increased synthesis of collagen protein in 
the extracellular matrix composed predominantly of type I collagen and to a lesser extent type III collagen (Thomas 
et al., 2007). 
In addition, myocardial fibrosis is characterized by dysregulated collagen turnover (increased synthesis 
predominates over unchanged or decreased degradation) and excessive diffuse collagen accumulation in the 
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interstitial and perivascular spaces. This dysregulation of collagen turnover takes place mainly in phenotypically 
transformed fibroblasts, termed myofibroblasts. (Norshige et al., 2011) 
Cardiac fibroblasts differentiation into myofibroblasts 
Cardiac fibroblasts have greater quantities than cardiomyocytes in the heart tissue. They are quiescent in healthy 
heart tissue, and are responsible for ECM secretion to keep the integrity of the interstitial matrix. After MI, the 
death of cardiomyocytes activates immune response that induces cytokine and chemokine expression. This initiates 
the infiltration of neutrophils and mononuclear cells to the infarcted area. The neutrophils are then phagocytosed 
by macrophages after apoptosis. The macrophages are able to secrete profibrotic cytokines like TGF-β, 
Angiotensin II, and platelet-derived growth factor (PDGF). TGF-β binds to TGF-β receptors type I and II, and 
activates the TGF-β/Smad pathway to differentiate the cardiac fibroblasts into myofibroblasts (Shinde et al., 2014). 
TGF-β has been demonstrated as a major mediator of myofibroblast formation after MI. The formed 
myofibroblasts then produce excessive ECM to initiate the cardiac fibrosis (Shinde et al., 2014 and Leask et al., 
2015). 
Following myofibroblast differentiation, its number increases over a period of a few months in the infarcted 
area. More ECM is thus generated and deposited, leading to the increase of scar size. In the scar, the content of 
collagen type III-rich fibers increases in a few weeks. The fibers are then gradually replaced by stiffer type I 
collagen. The scar tissue matures when the collagen fibers are crosslinked. Unlike other scar tissues, 
myofibroblasts exist in the cardiac scar for many years, and continue generating ECM (Leask et al., 2015). 
Fibrocytes differentiation into myofibroblasts 
Fibrocytes are a type of fibroblast-like peripheral cells. These cells express fibroblast specific proteins, cluster of 
differentiation 31 and 45 (CD34 and CD45). In response to chemokines such as chemokine ligand 21 and 
chemokine ligand 12, fibrocytes migrate towards the injured area. Under the stimulation of TGF-β or endothelin-
1, fibrocytes differentiate into myofibroblast type cells with expression of α-smooth muscle actin, production of 
fibronectin and collagen, and loss of expression of CD34 and CD45. Besides TGF-β and endothelin-1, cytokines 
including Interleukin-13, Interleukin-14 and Platelet Derived Growth Factor (PDGF) also promote the fibrocytes 
to differentiate into myofibroblasts (Mori et al., 2005). 
Epithelial to mesenchymaltransdifferentiation 
Epithelial to mesenchymaltransdifferentiation (EMT) is another origin of myofibroblasts, which is a process of 
transdifferentiation from epithelial cells into myofibroblast-like cells. In the EMT process, the expression of 
mesenchymal marker is up-regulated while the expression of epithelial marker is downregulated. TGF-β1 plays a 
key role in this process. While the roles of other cytokines in EMT are still in debate, strong evidences suggest 
that TNF α and Interleukin-1β are capable of accentuating the effect of TGF-β1 in driving EMT (Yamauchi et al., 
2010). 
Endothelial to mesenchymal transition 
While resident cardiac fibroblasts may be activated and transformed to myofibroblasts there is also the potential 
of fibroblasts originating from endothelial cells, suggesting an endothelial-mesenchymal transition (EndMT). For 
example, it has been shown that TGF-β1 induces endothelial cells to undergo EndMT, whereas bone morphogenic 
protein 7 (BMP-7) preserves the endothelial phenotype (Zeisberg et al., 2007). 
Endothelial to mesenchymal transition (EnMT) is currently thought to be a potential origin of myofibroblasts. 
EnMT was first proposed to be a phenomenon related to embryonic development until evidence indicated that 
EMT, EnMT can be driven by TGF-β (Types 1 and 2) and be augmented by TNF-α and IL-1β (Maleszewska et 
al., 2013). 
Cardiac fibroblast proliferation and differentiation into myofibroblasts are important processes in both types 
of cardiac fibrosis (Baudino et al., 2006). Myofibroblasts, which are called the activated cardiac fibroblasts, are 
considered as the major source that secret collagen and other extracellular matrix (ECM) proteins during the 
formation of fibrosis (Travers et al., 2016, Baudino et al., 2006, and Susane et al., 2010).  
 
1.4 Signaling pathways and their association with Cardiac Fibrosis 
The RAAS and TGF-β signaling pathways are major factors that are involved in the activation of cardiac 
fibroblasts and formation of tissue fibrosis. Administration of angiotensin II or aldosterone has been shown to 
stimulate collagen and other ECM protein expression and secretion from cardiac fibroblasts (Lijnen et al., 2000). 
Several members of the TGF-β family are involved in the regulation of inflammation and fibrosis (Euler et al., 
2015). The TGF-β1 signaling pathway is an important component in the switch from inflammation to fibrosis 
(Dobaczewski et al., 2011).  
In chronic conditions, activation of RAAS, TGF-β and other pro-fibrotic signaling pathways can induce 
interstitial fibrosis in the heart and other organs (Piera-Velazques et al., 2011). 
In the event of an MI, activation of NFκB was observed in different cells and subsequently drives the 
expression of a large panel of genes. These genes produce pro-inflammatory cytokines such as Tumor Necrosis 
Factor-α (TNF-α) and interleukin proteins that subsequently help recruit leukocytes and initiate the inflammation 
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responses (Prabu and Frangogiannis, 2016 and Sun et al., 2007). 
In addition to these traditional signaling pathways, epigenetic regulation has drawn attention for their 
regulating role in cardiac fibrosis. Numerous MicroRNAs were found to be either pro- or anti-fibrotic (Lakatta et 
al., 2003). Some anti-fibrotic MicroRNAs such as the miR-29 microRNA family directly target the mRNA of 
several collagen isoforms, fibrilin 1, elastin, and matrix metalloprotease 2 (MMP2) and thus prevent over 
expression of these ECM proteins (Stein et al., 2010). When the anti-fibrotic MicroRNAs are reduced in disease 
state, syntheses of collagen and other ECM protein increase and promoting the development of fibrosis. 
The role of the Renin–Angiotensin-Aldosterone System (RAAS) 
A large body of evidence indicates that the activation of Renin–Angiotensin-Aldosterone System (RAAS) might 
play a central role in cardiac aging and in age-associated fibrotic remodeling. Even in the absence of overt 
hypertension, arterial vascular walls become less compliant with age, resulting in some degree of pressure overload. 
ANG II concentrations increase significantly in aged the heart, probably due to an increase tissue level of 
angiotensin II converting enzyme (ACE). ANG II promotes cardiomyocyte hypertrophy (Euler et al., 2015 and 
Ventura Clapier et al., 2008) and stimulates fibroblast proliferation and expression of extracellular matrix proteins. 
 
Figure 1. Pathways involved in the pathogenesis of cardiac fibrosis in the senescent heart, the role of 
Angiotensin II Reactive Oxygen Species (ROS) (Adopted from Biernacka et al., 2011)    
The role of reactive oxygen species (ROS) 
Within the cells, ROS are produced in multiple compartments; however, mitochondria contribute to the majority 
of ROS generation as a byproduct of electron transfer during oxidative phosphorylation. Mitochondrial DNA 
(mtDNA), lipids, and proteins are therefore at the highest risk from free radical-induced damage and dysfunction.  
Several studies have documented an age related impairment of mitochondrial function associated with increased 
production of ROS. The heart, with its high metabolic demand is rich in mitochondria and is especially vulnerable 
to mitochondrial oxidative damage. Impairment of mitochondrial function has been widely documented in heart 
failure in both human patients and mouse models (Ventura Clapier et al., 2008). Moreover a significant increase 
in superoxide radical production was seen in mitochondria prepared from aging rat hearts. 
The role of TGF-β 
TGF-β may play an essential role in cardiac fibrosis by inducing myofibroblasttransdifferentiation and by 
enhancing matrix protein synthesis by cardiac fibroblasts (Bujak et al., 2007). In addition, TGF-β may exert potent 
matrix-preserving actions by suppressing the activity of mixed metalloproteases and by inducing synthesis of 
protease inhibitors, such as PAI-1 and TIMPs. Beyond its effects on mesenchymal cells, TGF-β also induces 
hypertrophic effects on cardiomyocytes and modulates the function of inflammatory cells (Shi et al., 2003).  
Both ROS and ANG II may activate TGF-β signaling pathways in the senescent heart. ROS activate TGF-β and 
upregulate its downstream fibrogenic effector, connective tissue growth factor (CTGF). In addition, ANG II 
markedly upregulates TGF-β1 synthesis by cardiac fibroblasts and myofibroblasts. ANG II-induced TGF-β 
upregulation is followed by the development of cardiac fibrosis (Rosenkranz et al., 2004). 
The role of β-adrenergic signaling 
Activation of β-adrenergic signaling increases heart rate, contractility and afterload, enhancing cardiac metabolic 
demand. Chronic activation of β-adrenergic signaling is deleterious to the heart; several clinical trials have 
demonstrated that inhibition of β-adrenergic signaling by β-blockers provides survival benefit in patients with 
heart failure. Mice with disruption of adenylatecyclase type 5 (AC5), a major mediator of β-adrenergic signaling 
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in the heart, had prolonged life span and were protected from cardiac aging, exhibiting reduced age-dependent 
cardiac hypertrophy and attenuated fibrosis (Stein et al.,2010 and Rosenkranz et al.,2002). 
TGF-β1-overexpressing mice exhibited enhanced β-adrenergic signaling and significant cardiac hypertrophy 
accompanied by interstitial fibrosis. On the other hand, loss of one TGF-β1 allele in TGF-β1 heterozygous mice 
appears to ameliorate age-associated myocardial fibrosis and improve left ventricular compliance (Brooks et al., 
2000).  
The role of Endothelin 
The endothelin family of peptides is typically recognized for its vasoconstrictive properties and is now beginning 
to be appreciated for its potential role in promoting tissue fibrosis. Although originally thought to be secreted 
predominantly by endothelial cells, endothelin-1 (ET-1) is now understood as a significant profibrotic peptide 
released by both inflammatory cells and fibroblasts in the lung (Shi-Wen et al., 2006). 
There exist two known receptors for ET-1 in the heart, the ETA and ETB receptors, which have been shown 
to play differing and sometimes opposing roles. These receptors are primarily expressed by endothelial cells; 
however, new data define expression on multiple cell types including cardiomyocytes and cardiac fibroblasts, 
along with some immune cells, such as macrophages (Chen et al., 2006). 
Importantly, ET-1 activation of the ETA receptor is known to increase collagen production in isolated human 
cardiac fibroblasts. Furthermore, myofibroblasts isolated from scar tissue after experimental MI possess elevated 
levels of ET-1, suggesting an important function for endothelin within these cells. Although known to have 
fibroblast-activating properties of its own, ET-1 also acts as a downstream mediator of both ANG II and TGF β to 
promote myofibroblast persistence in pulmonary fibrosis (Dashwood et al., 2011). 
ET-1 signaling is thought to interact with ANG II as well. For example, the development of cardiac fibrosis 
and hypertrophy in response to ANG II stimulation is impaired in mice in which ET-1 is ablated in endothelial 
cells (Hafizi et al., 2004).  
Endothelin antagonists are currently approved for the treatment of pulmonary hypertension, and many think 
they will be additionally efficacious in the treatment of pathological fibrosis in the heart. Bosentan, a nonselective 
endothelin receptor antagonist, although used clinically for the treatment of pulmonary hypertension, can improve 
cardiac function and reduce infarct size after myocardial ischemia/reperfusion injury in rats. Next generation 
endothelin receptor subtype-specific antagonists, such as Ambrisentan and Darustentan that are proving to be 
highly beneficial in the treatment of pulmonary hypertension, may prove more efficacious and help define receptor 
specificity that may be required for salutary effects (Katwa et al.,2003). 
 
2. Currently available treatment approaches targeting cardiac fibrosis  
2.1 Antihypertensive agents  
In vivo and in vitro experiments have shown that the effector hormones of the Renin angiotensin- aldosterone 
system, angiotensin II and aldosterone stimulate fibroblast-mediated collagen synthesis (Brilla et al., 1994).  
Most of the tested antihypertensive therapies have been shown to reduce fibrosis in animal models. In a rat 
model of aortic banding associated with renal artery ligation, an Angiotensin converting enzyme (ACE) inhibitors, 
a β-blockers and a calcium-channel blocker all reduced left ventricular (LV) fibrosis (Brilla et al., 2000).  
However, anti-hypertensive drugs do not all seem to exert similar effects in patients. In hypertensive patients 
treated with either Lisinopril (n = 18) or hydrochlorothiazide (HCTZ) (n = 17), endomyocardial biopsies at baseline 
and 6 months revealed a decrease of collagen volume fraction (CVF) only in the group treated with the ACE 
inhibitor . With Lisinopril, CVF was reduced significantly, whereas no regression of myocardial fibrosis occurred 
with Hydrochlorothiazide (Funck et al., 2000). 
A comparison between Losartan (n = 21) and Amlodipine (n = 16) given for one year revealed that while 
changes in blood pressure during treatment were similar in the two groups, only Losartan resulted in significant 
decrease in CVF (Lopez et al.,2001). 
2.1.1 Angiotensin Converting Enzyme Inhibitors (ACEi)  
Angiotensin II suppresses the collagenase activity that synergistically leads to progressive collagen accumulation 
within the cardiac interstitium (Brilla et al., 1994, Brilla et al., 2000, Funck et al., 2000 and Lopez et al., 2001).  
Angiotensin-converting enzyme inhibitors remain a first-line treatment for hypertension. The ACE inhibitor 
Lisinopril has been shown to induce regression of myocardial fibrosis in rats with genetic hypertension and LV 
hypertrophy (Brilla et al., 1996). 
In spontaneously hypertensive rats, LV hypertrophy and myocardial fibrosis could be regressed and LV 
diastolic function could be improved by treatment with the angiotensin-converting enzyme (ACE) inhibitor 
Lisinopril (Funck et al., 2000 and Brilla et al., 1996).  
ACE inhibitors can prevent the LV remodeling process that accompanies cardiac dysfunction after MI. These 
findings suggest that ACE inhibitors prevent LV remodeling after MI by mechanisms other than inhibition of 
angiotensin AT1 receptor mediated effects (Yoshiyama et al., 2005).  
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2.1.2 Angiotensin Receptor Blockers (ARBs)  
ARBs have also been shown to have favorable effects on ventricular fibrosis. Losartan and Olmesartan have 
improved healing after MI in rodents ((Scheiffer et al., 1994, Matsusaka et al., 2006). ARBs have also been shown 
in small clinical studies to reduce fibrosis biomarkers. For example, Candesartan reduced fibrosis biomarkers in 
153 patients with atrial fibrillation (this could reflect either atrial or myocardial fibrosis reduction) (Kawamura et 
al., 2010).  
Irbesartan, another ARB possesses anti-fibrotic activity and offers protection against myocardial fibrosis, due 
to regulation of angiotensin II activity through blockade of Angiotensin (AT1) receptors which might attenuate 
the endoplasmic reticulum stress and thus inhibit myocardial fibrosis via inhibition of oxidative stress. The 
regulation of antioxidant defensive enzymes may be involved in anti-fibrotic effect of Irbesartan (Vandaria et al., 
2015).  
2.1.3 Aldosterone antagonists  
The mineralocorticoid receptor antagonist Spironolactone has been shown to be a promising drug in animal models 
and has been recently proposed in clinical conditions associated with fibrosis like metabolic syndrome and obesity.  
A comparison between Spironolactone 25 mg/day and placebo for 6 months in 80 patients with metabolic 
syndrome already treated with ANG II inhibition revealed that only the Spironolactone treated group showed 
significant improvement of LV diastolic function and parallel decreases in PICP and PIIINP levels (Azibani et 
al.,2012 and Kosmala et al.,2011). 
Interesting results have also been obtained in a small study of 44 patients with diastolic HF who were treated 
with either placebo or the mineralo-corticoid receptor antagonist Eplerenone (Mak et al., 2009).  
A study comparing the percentage of fibrosis between groups taking Spironolactone, Lisinopril and Atenolol 
using left ventricular end-diastolic pressure (LVEDP) as the covariate, Spironolactone proved to be the most 
effective drug for the reversal of fibrosis (Paul et al.,2005).  
A study conducted regarding the effect of Potassium Canrenoate, an aldosterone antagonist in reducing 
Isoprenaline induced fibrosis revealed that antagonism of aldosterone receptors with Potassium Canrenoate 
interacts with cardiac remodeling after the acute administration of high doses of Isoprenaline. The drug reduces 
the extent of fibrosis and such effect is associated with a greater left ventricular enlargement (Bos et al., 2004). 
 
2.2 Anti-inflammatory agents  
Targeting some of the most powerful pro-inflammatory cytokines (TNF-α, IL-1 and IL-6) could have beneficial 
effects on cardiac fibrosis. The TNF-α pathway is clearly involved in cardiac fibrosis in various basic models 
(Duerrschmid et al., 2013).  
2.2.1 Galectin 3 Inhibitors  
Galectin-3 is a member of the lectin family and has been shown to be involved in inflammation, cell adhesion and 
activation, including in heart diseases. It was found to be over expressed in failing hearts in a rat model of HF. 
Myocardial biopsies revealed that galectin-3 was over expressed at an early stage specifically in the rats that later 
developed HF. Galectin-3 was proposed to represent a biomarker for activated macrophages, but could also be 
involved in activation of cardiac fibroblasts. Importantly, recombinant galectin-3 induced cardiac fibroblast 
proliferation, collagen production and an increase of collagen I over collagen III (De Boer et al., 2010 and Sharma 
et al., 2004).  Sustained delivery of drugs that decrease inflammation in the infarcted hearts after MI may decrease 
the inflammation cytokines-associated myofibroblast formation, thereby reducing cardiac fibrosis (Sharma et al., 
2004). 
2.2.2 Ibuprofen 
Ibuprofen is a cyclo-oxygenase inhibitor with anti-inflammatory property. It directly inhibits leukocyte activation 
and accumulations, and decreases the production of leukocyte attractant and activator leukotriene B4. Vu et al. 
injected ibuprofen-containing hyaluronic acid hydrogel into infarcted pig hearts, and found that cardiac fibrosis 
was significantly decreased compared to the hydrogel only group (Vu et al., 2015). 
 
2.3 Selective heart rate-reducing agents 
2.3.1 Ivabradine 
β - blockers are groups of drugs that inhibit cardiac fibroblast growth and hence inhibit cardiac fibrosis (Turner et 
al., 2003). The If current inhibitor Ivabradine provides selective heart rate  reduction and has recently been 
introduced in the treatment guidelines for HF in patients with LV systolic dysfunction (Roubille et al.,2013). 
In a rabbit model of diastolic dysfunction, Ivabradine attenuated LV diastolic dysfunction and also reduced 
significantly both atrial and ventricular fibrosis as well as ventricular collagen type I. Interestingly, Ivabradine also 
decreased plasma ANG II levels in that study (Busseuil et al.,2010). 
In support of this notion, Ivabradine was found more efficacious to reduce cardiac fibrosis than Metoprolol 
in mice models of HF (Becher et al., 2012). Ivabradine could reduce systemic inflammation and pro-inflammatory 
cytokines (Li et al., 2013). 
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Both Ivabradine and Carvedilol similarly attenuated myocardial lesions and fibrosis, inhibited nitric oxide 
(NO) synthesis by inducible NOS, and decreased the production of TNF-α and IL-6. Beta-blockers could also be 
of interest, through the reduction of HR and blood pressure, but also by other effects including NO production and 
anti-oxidative action as has been reported for the beta-blocker Carvedilol (Leki et al., 1989 and Bartholomeu et 
al., 2008). 
 
3. Novel treatment targets of cardiac fibrosis  
3.1 Epigenetic based therapies  
3.1.1 MicroRNAs  
MicroRNAs (miRNAs) are short, noncoding RNAs (≈22 nucleotides) that are formed in a highly regulated process 
in the nucleus and are then transported into the cytosol, in which they are processed further (Lorenzen et al., 2012 
and Quiat et al., 2013).  
MiRNAs modify gene expression by down regulating genes at the post-transcriptional level during various 
developmental or disease processes. These ≈22 nucleotide RNAs bind to their targets in the 3’ untranslated region 
(UTR) of messenger RNAs (mRNAs) to inhibit translation or evoke degradation of the mRNA (Quiat et al., 2013 
and Napoli et al., 2016). MiRNAs are highly conserved in different species and are thought to regulate 50% of the 
genome. In cardiac development, miRNAs are needed for the formation of normal, functional heart tissue (Napoli 
et al., 2016). 
Initially, primary miRNAs (pri-miRNA) are generated in the cellular nucleus by the transcription machinery 
and are then processed by the RNase-III-type enzyme Drosha to form so called precursor miRNAs (pre-miRNAs). 
Following exportation into the cytoplasm, miRNAs are processed by the ribonuclease Dicer into small 20–23 
nucleotide long miRNA duplexes. Finally, miRNAs are incorporated into RNA Induced Silencing Complexes 
(RISC) to silence gene expression at the post-transcriptional level by targeting messenger RNAs (mRNAs) with 
the result of mRNA degradation or by translational inhibition finally leading to target protein repression (Lorenzen 
et al., 2012,Quiat et al., 2013, Napoli et al., 2016 and Ooi et al.,2016). 
With miRNAs highly integrated into every cellular event, the potential impact on cardiac function is profound 
when considering the ramifications of misregulation of processes such as fibrosis. Upregulation of miRNAs may 
be beneficial for normalizing disease states; however, over expression may tilt the balance in the wrong direction 
(Quiat et al., 2013, Bauersachs et al., 2016 and Liang et al., 2012).  
MicroRNAs have recently come into focus as powerful regulators of gene expression, and they fundamentally 
influence the pathogenesis of different pathological events, including cardiac fibrosis. The miRNA expression 
patterns change in various cardiovascular diseases, such as myocardial infarction, cardiac hypertrophy and heart 
failure (Bauersachs et al., 2016).  
Non-myocyte myocardial cells, such as endothelial cells and fibroblasts, play a key role in remodeling 
processes, contributing to the development of heart failure. Among others, miR-21 and miR-29 have been studied 
most intensively in relation to cardiac fibrosis (Liang et al., 2012).  
Cardiac fibroblasts are enriched with certain miRNAs, such as miR-21 (Liu et al., 2010 and Zhong et al., 
2011), which regulates the ERK–MAP kinase signaling pathway via targeting sprouty-1. By this mechanism, 
fibroblast survival and growth factor secretion, apparently regulating the extent of interstitial fibrosis and cardiac 
hypertrophy, is controlled. In vivo silencing of miR-21 by a specific cholesterol-based antagomir in a mouse 
pressure-overload-induced disease model reduced cardiac ERK–MAP (Extracellular signal Regulated Kinase – 
Mitogen Activated Protein) kinase activity, inhibited interstitial fibrosis and attenuated cardiac dysfunction. In 
addition, recently it has been shown that miR-21 antagonism blocks endothelial–mesenchymal transition in TGF- 
β treated endothelial cells as well as in vivo in a cardiac hypertrophy model resulting in reduced fibrosis 
development. Strikingly, the effects of miR-21 inhibition on fibrosis prevention were validated in other organs 
often affected by pathological fibrosis during diseases such as the lung (Liu et al., 2010) and the kidney (Volkmann 
et al., 2012). Thus, miR-21 inhibition may represent a general approach to inhibit exaggerated organ fibrosis. 
MiR-21 was also associated with the TGF- pathway and TGF- receptor, in which over expression of miR-
21 led to increased cardiac fibrosis due to the TGF- mediated endothelial-to-mesenchymal transition. This 
miRNA was upregulated in the mouse myocardium after cardiac stress and in the myocardial tissue of patients 
with aortic stenosis. In these patients, miR-21 was only present in interstitial cells and correlated with collagen 
expression in the heart (Zhong et al., 2011 and Volkmann et al., 2012). 
In addition, in cardiac fibrosis in response to cardiac hypertrophy and failure, miR-21 is specifically enriched 
in cardiac fibroblasts and regulates the ERK – MAP kinase signaling pathway through inhibition of sprout homolog 
1. By this mechanism, miR-21 promotes fibroblast survival and growth factor secretion. In contrast, silencing of 
miR-21 with a specific antagonist (antagomir) culminated in a reduction of cardiac extracellular signal-regulated 
kinase– mitogen-activated protein kinase activity, inhibition of interstitial fibrosis, and improvement of cardiac 
dysfunction (Liang et al., 2012, Zhong et al., 2011 and Volkmann et al., 2012). 
Wang et al. showed that miR-24 could interfere with TGF signaling by targeting the pro-protein convertase, 
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furin, and subsequently down regulate the level of TGF in cardiac fibroblasts (Wang et al., 2012). 
MiR-29 was identified to target several collagens, including collagen type 1A1, collagen type 1A2, and 
collagen type 3A1, as well as fibrillin 1, thus promoting extracellular matrix deposition after myocardial infarction 
(MI). Specifically, after MI, the miR-29 family is downregulated in vivo, thereby derepressing its targets and 
resulting in cardiac fibrosis (Van Rooij et al., 2008).  
In a pioneer study by Olson’s group, expression of miR-29 family members (miR-29a, miR-29b and miR-
29c) negatively correlated with expression of genes involved in ECM production and fibrosis after experimental 
myocardial infarction. Furthermore, the miR-29 family regulates the expression of pro-fibrotic genes, including 
extracellular matrix genes elastin, fibrillin 1 (Fbn1), collagen type I, 1 and 2 (Col1-1, Col1-2) and collagen type 
III, -1 (Col3-1) (El Vegteret et al., 2016).  
In contrast to a down regulation, during aging, an upregulation of miR-29 was seen in the aorta of mice and 
the increased expression of miR-29 family members was associated with a profound down regulation of numerous 
ECM components in aortas of aged mice and during aneurysm formation (Boon et al., 2011). Of clinical relevance, 
miR-29b levels were also profoundly increased in human thoracic aneurysms. 
In vitro knockdown of miR-29 resulted in increased cardiac fibrosis whereas over expression resulted in 
reduced cardiac fibrosis. In vivo, miR-29b over expression by miR-29b transfection into the heart attenuated the 
progression of fibrosis and led to an improvement of cardiac function. The TGF-/Smad3 signaling pathway has 
been described as playing a crucial role in cardiac fibrosis as target of miR-29 (Zhang et al., 2014 and Zhou et al., 
2012).  
Thioredoxin, which regulates in part cardiomyocyte hypertrophy, leads to an increase in expression of the let-
7 family including miR-98. To evaluate the function of miR-98 in the heart in vivo, adenoviral miR-98 or antimiR-
98 was injected into mouse hearts. ANG II-induced increases in hypertrophy, cardiomyoctye apoptosis and fibrosis 
were attenuated by Ad-miR-98 and significantly enhanced by AdantimiR- 98. MiR-98 negatively regulates ANG 
II-induced cardiac hypertrophy and the accompanying histopathologic changes in vivo and thus is an attractive 
target for the treatment of cardiac remodeling. (Yang et al., 2011) MicroRNAs have been demonstrated to be 
powerful antifibrotic agents (Thum and Lorenzen, 2016). 
One of the first studies that used an antagomir to inhibit a MiRNA involved in cardiac hypertrophy was 
performed by Care and coworkers. This group implanted mice subcutaneously with osmotic minipumps for a 
continuous delivery of a cholesterol-based antagomir targeting miR-133. After 1 month of infusion, 
echocardiographic analysis showed a marked increase in cardiac hypertrophy suggesting that miR-133 mimics 
may be of therapeutic relevance (Thum and Lorenzen, 2016 and Zhao et al., 2015). 
In a rat model of MI, the expression of miR-101a and miR-101b (miR-101a/b) in the peri-infarct area was 
decreased, whereas the cardiac performance improved after adenovirus-mediated over expression of miR-101a as 
evidenced by echocardiography and hemodynamic measurements (Pan et al.,2012). Importantly, interstitial 
fibrosis was decreased by the treatment in that study. 
Recently, miR-101and miR-101a were found to negatively regulate TGF signaling through targeting of TGF 
receptor type 1 (TGF-R1) and c-Fos (Nagpal et al., 2016).  Cardiac fibrosis is significantly suppressed by 
upregulation of miR-101a in the rat myocardial infarction model. 
Several other miRNAs have been identified as also targeting collagens and TGF_ signaling to play a role in 
fibrogenesis. The role of miR-133a in myocardial fibrosis and electrical depolarization in pressure-overloaded 
adult hearts may reflect its regulatory effects on the expression of Col1_1, Serca2a and calcineurin (Duisters et al., 
2009). MiR-125b is a pro-fibrotic MiRNA via targeting of apelin, one of the key fibrogenesis repressors in the 
heart (Da Costa et al., 2010).  
Another group showed involvement of miRNAs in cardiac hypertrophy; miR-199b is a direct 
calcineurin/nuclear factor of activated T cells (NFAT) target that increases in expression during mouse and human 
heart failure thus being a potential interesting target for therapies. Indeed, in vivo inhibition of miR-199b by a 
specific intraperitoneally administered antagomir normalized reduced nuclear NFAT activity and caused inhibition 
and even reversal of cardiac hypertrophy and fibrosis in mouse models of heart failure (Da Costa et al., 2010). 
In another mouse model, genetic deletion of miR-214 caused loss of cardiac contractility, increased apoptosis 
and excessive fibrosis in response to ischemia-reperfusion injury (Arin et al., 2012).  
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Table 1 Recent evidence investigating the role of circulating miRNAs as biomarkers in several cardiovascular 
diseases. Taken from (Napoli et al., 2016) 
 
 
3.2 Targeting Receptors  
3.2.1 Adenosine receptors  
Adenosine, a purine nucleoside generated extracellularly from adenine nucleotides released by cells as a result of 
direct stimulation, hypoxia, trauma, or metabolic stress, is a well-known physiologic and pharmacologic agent 
(Jackson et al., 1996). 
 
Figure – 2 formation of adenosine from adenine nucleotides (taken from Jackson et al., 1996) 
Adenosine is formed both intracellularly and extracellularly from adenine nucleotides, which are sequentially 
dephosphorylated to adenosine. Intracellular adenosine may be transported into the extracellular space via 
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facilitated transport, and extracellular adenosine is also taken up by cells through the same transporter, equilibrative 
nucleoside transporter 1(ENT1). Two cell surface molecules, CD39 and CD73 (nucleoside triphosphate 
phosphohydrolase and ecto-50-nucleotidase, respectively), catalyze the dephosphorylation of adenine nucleotides 
to adenosine in the extracellular space. 
Adenosine is synthesized by the cardiac wall and exerts numerous cardioprotective and anti-vaso occlusive 
actions. The interstitial levels of this nucleoside are elevated in certain pathophysiological conditions (Bruce et al., 
2011 and Jackson et al., 1996).  
Recent studies demonstrate that adenosine, acting at its receptors, promotes wound healing by stimulating 
both angiogenesis and matrix production. Subsequently, adenosine and its receptors have also been found to 
promote fibrosis (excess matrix production) in the skin, lungs, and liver, but to diminish cardiac fibrosis (Headrick 
et al., 2013).  
In addition to a clear role in cardio protection, adenosine exerts a multitude of actions on the physiological 
regulation of the heart, including coronary vasodilation, heart rate control and AV nodal conduction, angiogenesis, 
myocardial hypertrophy and remodeling and fibrosis (Bruce et al., 2011 and Headrick et al., 2013). 
Exogenous as well as endogenous adenosine inhibits Fetal Calf Serum (FCS)-induced proliferation of CFs 
(Cardiac Fibroblasts). Because some factors that inhibit cell proliferation also inhibit cellular hypertrophy and 
ECM synthesis, it was hypothesized that adenosine may be an endogenous factor that attenuates hypertrophy of 
and collagen synthesis by CFs (Dubey et al., 1997).  
Cardiomyocytes, vascular smooth muscle cells, and endothelial cells, both vascular and cardiac, have several 
metabolic pathways for generating large amounts of adenosine. For example, it has been shown that endothelial 
cells synthesize adenosine and have an adenine pool that is two to three times greater than that of hepatocytes 
(Dubey et al., 1997 and Mullane et al., 1995).  
Cardiac Fibroblasts (CFs), which constitute 60% of the total heart cells, can also synthesize adenosine. 
Therefore, substantial amounts of adenosine are synthesized locally within the cardiac wall, in part by CFs, thus 
ensuring pharmacologically active levels of adenosine in the heart (Dubey et al., 1998). 
The AR family is comprised of four Class - A G protein coupled receptors (GPCRs), the A1, A2A, A2B and 
A3 ARs. They exert distinct pharmacological actions through differential coupling to intracellular G proteins; the 
A1 AR and A3 AR preferentially activate Gi=o proteins to inhibit adenylyl cyclase activity and subsequent cAMP 
production, while the A2A AR and A2B AR preferentially stimulate Gs proteins to activate adenylyl cyclase 
activity and increase cAMP accumulation. The A2B AR has also been shown to stimulate robust Gq=11 protein 
activation in some cell types. ARs, and the A2B AR in particular, have also been shown to couple to additional 
transmembrane and intracellular proteins, which may influence downstream signal transduction (Fredholm et al., 
2001 and Sun et al., 2016). 
All four ARs are expressed in the heart and synchronous activation of multiple subtypes’ results in both 
complementary and opposing signal transduction for the fine tuned regulation of cardiac function. Interestingly, 
both pro- and anti-fibrotic actions have been attributed to AR activation. (Bruce et al., 2011, Chan et al., 2009 and 
Karmouty et al., 2013) to date, the preponderance of evidence has implicated the A2B AR in cardiac fibrosis 
(Novitskaya et al., 2016). 
A number of studies demonstrate that stimulated adenosine receptors play different roles in the pathogenesis 
of fibrosis depending on the tissue. Adenosine A2B receptors in the heart inhibit fibrosis, whereas these same 
receptors promote fibrosis in the lungs. In contrast, in the skin, liver, and lungs, adenosine A2A and A2B receptors 
both mediate an increase in fibrosis. It is also striking that different adenosine receptors appear to play a dominant 
role in fibrosis in different organs; adenosine A2A receptors are the dominant receptors in the skin, peritoneum, 
and liver but A2B receptors are responsible for pulmonary fibrosis (Bruce et al., 2011 and Vecchio et al., 2017).  
Adenosine has been implicated in cardioprotective events, notably in the context of cardiac hypertrophy. Its 
levels are elevated in cardiac hypertrophy, experimental hypertension, acute and chronic phases of myocardial 
infarction and during the progression of heart failure. Adenosine exerts anti-hypertrophic and anti-adrenergic 
effects and is proposed to be cardioprotective in the setting of heart failure (S-L Puhl et al., 2016). 
Growth-arrested confluent cardiac fibroblast monolayers were stimulated with 2.5% fetal calf serum (FCS) 
in the presence and absence of adenosine, 2-chloroadenosine (stable adenosine analogue), or modulators of 
adenosine levels including (1) erythro-9-(2-hydroxy-3-nonyl) adenine (adenosine deaminase inhibitor), (2) 
dipyridamole (adenosine transport blocker), and (3) iodotubericidin (adenosine kinase inhibitor) (Dubey et al., 
1998).  
All agents inhibited in a concentration-dependent fashion FCS-induced [3H] proline and [3H] leucine 
incorporation. These effects were blocked by KF17837 (selective A2 antagonist) and 1,3-dipropyl-8-(psulfophenyl) 
xanthine (A1/A2 receptor antagonist) but not by 8-cyclopentyl-1,3-dipropylxanthine (selective A1 antagonist), 
thus excluding the participation of A1 receptors. The lack of effect of CGS21680 (selective A2A agonist) excluded 
involvement of A2A receptors, thus suggesting a major role for A2B receptors. Comparisons of the inhibitory 
potencies of N6-cyclopentyladenosine (selective A1 agonist), 59-N-ethylcarboxamidoadenosine (A1/A2 agonist), 
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and 59-N-methylcarboxamidoadenosine (A1/A2 agonist) were consistent with that of an A2B receptor subtype 
mediating the inhibitory effects. It is concluded that adenosine inhibits FCS-induced collagen and total protein 
synthesis in cardiac fibroblasts via activation of A2B receptors. These studies suggest, but do not prove, that 
endogenous adenosine may protect against cardiac fibrosis (Bruce et al., 2011, Dubey et al., 1997 and Dubey et 
al., 1998). 
Dubey and colleagues have reported that adenosine A2B receptor activation inhibits cardiac fibroblast 
production of collagen in vitro. In agreement with these original findings, Wakeno and colleagues have reported 
that adenosine A2B receptor stimulation diminishes fibrosis and remodeling of the myocardium after infarction 
(Dubey et al., 1998 and Wakeno et al., 2006).  
Among the four subtypes of adenosine receptors (AdoRs), the A2B AdoR was expressed at the highest level 
in human cardiac fibroblasts (HCF). NECA, a stable analog of adenosine, significantly increased the release of IL-
6 in a concentration-dependent manner. In addition, NECA increased the expression of a-smooth muscle actin and 
a-1 pro-collagen, and the production of collagen from HCF. The effects of NECA on release of IL-6, collagen, 
ST-2, and PAPPA and expression of a-smooth muscle actin and a-1 pro-collagen were completely abolished by a 
selective A2B AdoR antagonist, GS-6201 (Wakeno et al., 2006).  
A2B AdoR is the predominant subtype of AdoRs expressed in primary human HCF. Activation of this 
receptor increases the release of IL-6, production of collagen, expression of fibrotic markers and release of 
biomarkers of CVD. These findings suggest that A2B AdoR might mediate the fibrotic response in heart diseases 
(Hongyan et al., 2010). 
Deletion of 5′ ectonucleotidase, one of the main regulators of adenosine metabolism, and the subsequent 
reduction in adenosine levels led to pronounced cardiac hypertrophy in a rat model of experimental hypertension, 
while stimulation of adenosine receptors attenuated cardiomyocyte hypertrophy in this model (Wakeno et al., 2006 
and Xu et al., 2008).  
Xu et al presented that activation of adenosine A1 receptors prevented phenylephrine-mediated 
cardiomyocyte hypertrophy and cardiac fibrosis in a model of compensated hypertrophy and that this 
cardioprotection is accompanied by up-regulation of the A1 receptors. These data suggest that full or partial 
agonists at adenosine A1 receptors may also mitigate cardiac remodeling and thus potentially dysfunction in 
response to α1-adrenoceptor stimulation (Xu et al., 2008). 
Besides its anti-hypertrophic effects, adenosine mediates anti-fibrotic effects through adenosine A2B 
receptors in vitro and in vivo. Furthermore, it is previously observed that adenosine prevents the expression of the 
pro-inflammatory cytokine TNF-α in the rat and failing human heart (Epperson et al., 2009).  
 
3.3 Targeting enzymes  
3.3.1 Lysyl Oxidase like 2 (LOXL2)  
Interstitial fibrosis plays a key role in the development and progression of heart failure. An enzyme that cross links 
collagen Lysyl Oxidase-like 2 (Loxl2) is essential for interstitial fibrosis and mechanical dysfunction of 
pathologically stressed hearts. In mice, cardiac stress activates fibroblasts to express and secrete Loxl2 into the 
interstitium, triggering fibrosis, systolic and diastolic dysfunction of stressed hearts. In diseased human hearts, 
LOXL2 is upregulated in cardiac interstitium; its levels correlate with collagen crosslinking and cardiac 
dysfunction. LOXL2 is also elevated in the serum of heart failure (HF) patients, correlating with other HF 
biomarkers, suggesting a conserved LOXL2-mediated mechanism of human HF (Jin Yang et al.,2016).  
Lysyl oxidase-like 2 (LOXL2) is upregulated in the interstitium of diseased mouse and human hearts. 
Increased LOXL2 expression leads to increased TGF-β 2 production, triggering the formation and migration of 
myofibroblasts with enhanced collagen deposition and crosslinking in the hypertrophic regions of stressed hearts. 
These effects result in interstitial fibrosis and cardiac dysfunction (Jin Yang et al., 2016).  
In mechanically stressed hearts, LOXL2 expression is activated in the fibroblasts, which then release LOXL2 
proteins into the interstitial space, particularly in the hypertrophic area where the mechanical stress is highest. This 
suggests that LOXL2 activation is a response of cardiac fibroblasts to enhanced mechanical stress to maintain 
structural integrity of the heart. Indeed, LOXL2 elevation has multiple biological effects that promote interstitial 
collagen formation. LOXL2 not only triggers myofibroblast transformation to enhance collagen production 
(through PI3K-AKT-mTOR and TGF-b), but also augments collagen strength (by crosslinking collagen fibers). 
LOXL2 also stimulates myofibroblasts migration to large areas of the heart, where these cells produce collagen 
fibers. Collagen fibers, once released into the interstitial space, are crosslinked by LOXL2 to form bundles of 
collagen that are much stiffer than isolated collagen fibers. Furthermore, activated fibroblasts secrete more LOXL2 
and collagen, creating a positive feedback loop to sustain the fibrotic process. All these factors, in combination, 
trigger diffuse interstitial fibrosis of pathologically stressed hearts (Jin Yang et al., 2016 and Davis et al., 2014). 
In patients with HF, LOXL2 levels are elevated in heart tissues and serum, its levels correlating with cardiac 
dysfunction and HF biomarker levels. In mice, LOXL2 activation is essential for cardiac fibrosis and HF 
development. The genetic or pharmacological inhibition of LOXL2 greatly reduces cardiac fibrosis and halts HF 
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progression. The human sample and animal efficacy studies, in combination, suggest a pathogenic role of LOXL2 
in cardiac fibrosis and human HF. Our studies therefore delineate a novel LOXL2-mediated HF mechanism and 
provide new insights into HF therapy (Davis et al., 2014, Kong et al., 2014 and Schelbert et al., 2015). 
The LOXL2-mediated stress reaction, although capable of reinforcing tissue strength in the face of increased 
mechanical stress, is ultimately maladaptive. Excessive amount of collagen fibers in cardiac interstitial space 
impede coronary vasodilation, oxygen diffusion and electromechanical coordination between cardiomyocytes, 
causing contractile abnormalities (systolic pump dysfunction). Meanwhile, the increase of collagen and its 
crosslinking stiffens the left ventricle, impairing ventricular relaxation and filling (diastolic pump dysfunction. 
Therefore, the LOXL2-mediated interstitial reaction leads to both systolic and diastolic abnormalities, revealing a 
novel therapeutic avenue for HF. The diastolic aspect of LOXL2 effects is particularly important, given the 
recognition and increasing prevalence of diastolic dysfunction as part of HF syndrome and the lack of approved 
therapy for HFpEF with primarily diastolic failure (Kasner et al., 2011). 
Although LOXL2 can interact with TGF-b in models of cancer and bone remodeling, the roles of LOXL2 
gene in HF have not been demonstrated in mouse genetic models in vivo. By generating a new LOXL2 genetic 
model with fibroblast-specific LOXL2 knockout, we showed crucial roles of LOXL2 in cardiac fibroblasts for 
stress-induced interstitial fibrosis and cardiac dysfunction. What remains unanswered is how LOXL2-mediated 
changes of extracellular collagen composition affect TGF-b processing and signaling and guide the cellular process 
of myofibroblast migration. Given that LOXL2 is transcriptionally activated in the stressed hearts, it will be 
essential to know what factors control the expression of LOXL2 gene in the hearts. Gene expression regulation 
can occur at the chromatin, transcription or posttranscriptional level, mediated respectively by epigenetic factors 
(chromatin-regulating factors, long noncoding RNAs), transcription factors and MicroRNAs. Understanding 
LOXL2 regulation will provide an opportunity to integrate cardiac fibrosis with epigenetics and RNA mechanisms 
of HF and to identify additional new targets for HF therapy (Atsawasunan et al., 2008). 
 
Figure 3 – a working model of how cardiac stress activates LOXL2 to trigger myofibroblast transformation, 
collagen synthesis, collagen crosslinking and myofibroblast migration, leading to diffuse ventricular fibrosis and 
dysfunction. (From Jin Yang et al., 2016) 
 
3.4 Targeting Oxidative stress  
3.4.1 N-Acetylcysteine 
Oxidative stress can contribute to the development of cardiac remodeling and fibrosis and these cardiac adaptations 
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can ultimately lead to failing of the myocardium. For example, oxidative stress has been demonstrated to increase 
the expression of cardiac collagen types I and IV and fibronectin and impair cardiac contractility in diabetic rats 
(Tsutsui et al., 2011).  
There is also evidence that oxidative stress plays a role in the development of angiotensin II-dependent cardiac 
fibrosis in rats (M-E Worou et al., 2013) and mice (Li et al., 2013).  
Reducing oxidative stress can minimize cardiac remodeling in the setting of HF. Cardiac-specific over 
expression of MST-1 induces apoptosis leading to cardiac remodeling (Yamamoto et al., 2003).  
Importantly, there is evidence that oxidative stress can induce apoptosis which provides a basis to target 
oxidative stress to reduce apoptosis-induced cardiac remodeling (Kumar et al., 2002).  
NAC can attenuate cardiac fibrosis and remodeling in the setting of HF. As these factors play major 
pathological roles in the development of HF (Beverly et al., 2016).  It has previously been shown that NAC has 
anti-fibrotic effects in experimental hypertrophic cardiomyopathy (Lombardi et al., 2009).  
There is evidence that left ventricular glutathione content is reduced in HF, and of particular interest, restoring 
the glutathione content via oral supplementation of its precursor, N-Acetylcysteine (NAC), reduced oxidative 
stress, and restored HF-related cardiac damage and function in rats. In addition to reducing oxidative stress, NAC 
treatment reduced the expression of the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-α) and its 
receptor expression in these rats (Adamy et al., 2007). 
Beverly et al discover two major novel findings in their study which aimed at assessing the role of NAC in 
reducing cardiac fibrosis and remodeling. First, cardiac perivascular and interstitial fibrosis and cardiac expression 
of collagen types I and III were greater in MST-1 mice compared to WT mice. Of interest, they found that 
perivascular and cardiac interstitial fibrosis were less in MST-1 mice treated with NAC compared to those treated 
with saline vehicle. Consistent with a reduction in cardiac fibrosis, cardiac collagen types I and III expression was 
also less in NAC-treated MST-1 mice than those treated with saline vehicle. These data provide direct evidence 
that NAC can prevent the development of cardiac fibrosis in the setting of HF. Together, these findings indicate 
that NAC can prevent the development of cardiac fibrosis in a mouse model of dilated cardiomyopathy. Secondly, 
it was found that the thickness of the interventricular septum was greater in MST-1 mice compared to WT mice. 
In NAC-treated MST-1 mice, the thickness of the interventricular septum was less compared to vehicle treated 
MST-1 mice. These findings indicate that NAC treatment can attenuate HF-dependent cardiac remodeling 
(Beverly et al., 2016 and A-H Talasaz et al., 2013). 
NAC treatment reduced serum levels of TNF-a, transforming growth factor β (TGF-β), matrix 
metalloproteinase 9 (MMP-9), and MMP-2 in patients with acute myocardial infarction (A-H Talasaz et al., 2013). 
These cytokines and enzymes play an important role in the development of cardiac fibrosis, remodeling, and 
subsequent cardiac dysfunction (Skyschally et al., 2007).  
Therefore, NAC is likely to simultaneously target multiple mechanisms which underpin the progressive 
worsening of cardiac function in HF. In particular, cardiac fibrosis remains an independent risk factor for 
cardiomyopathy-related morbidity and mortality (Leyva et al., 2012 and Gulati et al., 2013) and treatment 
interventions that effectively target cardiac fibrosis remain an unmet clinical need. 
There is evidence that perivascular fibrosis is associated with reduced coronary perfusion in patients with 
nonischemic HF. As impaired coronary perfusion can in turn have a direct impact on cardiac function, these 
findings provide a basis for targeting perivascular fibrosis in the treatment of HF. Beverly et al found that 
perivascular fibrosis was less in MST-1 mice treated with NAC compared to those treated with saline. Thus, the 
findings provide evidence that NAC can reduce cardiac perivascular and interstitial fibrosis associated with HF 
(Beverly et al., 2016 and Z Dai et al., 2012). 
It is also of interest to note that NAC can reduce oxidative stress, improve cardiac index, and reduce mortality 
in patients with acute myocardial infarction (Simon et al., 1996). Overall, these data provide evidence that NAC 
can provide cardioprotective effects to HF patients potentially via attenuation of cardiac fibrosis (Lombardi et al., 
2009 and Marian et al., 2006).  
 
4. Conclusions  
Despite the presence of different groups of drugs for treating cardiac fibrosis such as antihypertensive agents, anti-
inflammatory agents and heart rate reducing agents; the prevalence of cardiovascular diseases is increasing. 
Appreciably ample of novel therapeutic targets are being considered and few are under clinical trials; the 
effectiveness of which brings us with a green light as a preventive tool of cardiac fibrosis and as an indirect tool 
for prevention of heart failure and myocardial infarction. More importantly the implementation of epigenetic based 
therapies such as MicroRNAs is one of the first miracles in this aspect keeping in mind that few agents which were 
previously indicated for treatment of other medical conditions are nowadays reshuffled for the management of 
cardiac fibrosis.   
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5. Future perspectives  
There are tenths of new treatment targets for cardiac fibrosis that are under active clinical trials. It is believed that 
these newer targets can effectively battle against cardiac fibrosis in order to reduce the morbidity and mortality of 
cardiovascular diseases. In addition, this review discovered existing agents indicated for medical conditions other 
than cardiac fibrosis, as potential targets of therapy such as NSAIDs. These agents can be used effectively as 
alternatives until the newer agents come into existence.  
Furthermore newer targets, those targeting sodium potassium ATPase, Peroxisome Proliferator activated 
receptor Ɣ and Epoxide hydroxylase enzyme are on the way representing signaling pathways, receptors and 
enzymes respectively and hence increasing the probability that our world might be cardiovascular disease free in 
the near future. 
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